Burlingame (GLOBE NEWSWIRE), February 08, 2023 -- The global recombinant proteins market, according to Coherent Market Intelsights, is valued at US$ 2,808.4 millions in 2022. It is projected to grow 11.5% over the forecast period (2022-2030).
The Global Recombinant Protein Market: Key Trends and Analysis
The segment will see growth due to increased initiatives and research programs in antibody production. In January 2022, Vir Biotechnology, Inc., a company in the commercial stage of immunology, announced that it had extended its partnership with Bill & Melinda Gates Foundation to launch a new initiative for antibody research.
Request a Sample Copy of This Report URL
The Key Market Takeaways
Global recombinant proteins market is forecast to grow at 11.5% CAGR during the forecast period. Key players are involved in product launches for protein supplements. Muscle Pharm Corporation, which is a global producer and distributor of nutritional supplements for lifestyle branding and sports nutrition, announced in March 2022 that it would be entering the ready-to drink protein market with its new line of whey protein drinks. The brand new line of high-protein beverages, which will include over 20g of protein and be sugar-free and available in a range of flavors, will be sold under Muscle Pharm.
The dominant product type is the antibodies segment. This is due to the growing adoption of organic growth strategies such acquisitions by key players. It is expected that this will drive segment growth during the forecast period. Atlas Antibodies, which manufactures highly validated primary antibodies and evitria, which is a developer transient recombinant anti-body expression in Chinese hamster embryo (CHO) cells, was acquired by Atlas Antibodies in July 2021. The preferred expression system for the production of recombinant therapeutic proteins (RTPs) is CHO cells. This acquisition will bring together the antibody solutions from both companies and increase their business.
The biotechnology and pharmaceuticals companies segment will dominate the market over the forecast period on the basis of end users. Market players are increasing their fund raising activities for drug development. PDC line Pharma, a biotech company in clinical stage, announced that it had completed its Series B2 financing round. This is a new type of potent, scaleable active off-the-shelf vaccine against cancer. With South Korean and Belgian investors, the company raised US$ 20.3million (EUR17.5million) in total. PDC lung01 is one of the active immunotherapies for breast cancer that the company has developed based on a GMP-grade allogeneic therapeutics line of plasmocytoid cells- its PDC line. The series B funding round will fund the phase I/II trial.
Merck KGaA, OriGene Technologies, Inc., Feldan Therapeutics, ACROBiosystems, Abcam plc., Randox Laboratories Ltd., SOL GROUP, Proteintech Group, Inc, Planet Biotechnology, Inc., INFINITE ENZYMES, INC., ORF Genetics, GenScript, BTL Biotechno Labs Pvt Ltd., Prospec-Tany Technogene Ltd., BPS Bioscience, Inc., Sino Biological, Cape Bio Pharms, Abnova Corporation, Abnova Corporation, GeNext Genomics, GeNext Genomics
Buy-Now This Research Report URL
Segmentation of the Market:
Global Recombinant Protein Market, By Product Type:
Global Recombinant Protein Market, By Expression System:
Global Recombinant Protein Market By Application:
Drug Discovery and Development
Global Recombinant Protein Market By End User:
Biotechnology and Pharmaceutical Companies
Academic and Research Institute
Contract Research Organization
Global Recombinant Protein Market, By Region:
Sort by Country
Sort by Country
Rest of Latin America
Sort by Country
Rest of Europe
Sort by Country
Rest of Middle East
Similar Market Intelligence Reports
Market for Single-Use Bioreactors by Product (Single use Bioreactor Systems and Media Bags, Filtration Assemblies and Other Products), By Cell Types (Mammalian Cells, Bacteria and Yeast), By Molecule (Vaccines Monoclonal Antibodies and Stem Cells), By End Users (Pharmaceutical, Biopharmaceutical Industries, Contract Research Organizations and Other End Users) - Size, Share and Opportunity Analysis, 2022 to 2028
Market for Pulmonary surfactant in Pulmonary, by Type (Synthetic and Animal Derived Surfactant), and Drug Type (Poractant Alfa, Lucinactant and Calfactant), according to Indications (Respiratory Distress syndrome (RDS), Respiratory Diseases, Obstructive Lung Diseases, Other (chronic lung disease of prematurity and surfactant protein B deficiency), by Route of Administration(Intratracheal), by Distribution Channel, Online Pharmacies, Retail Pharmacies and Online Pharmacies, Asia Pacific and Africa), 2022- 2030
Coherent Market Insights, a global market intelligence and consultancy organization, focuses on helping our clients achieve transformative growth through helping them make key business decisions. Our headquarters is in India. We have a sales office in the United States and consultants in Japan and the United Kingdom. Our clients include players from over 57 countries and all business verticals. Our highly reliable and accurate reports create value for our clients. We also have a strong commitment to continue delivering measurable and sustainable results for clients post-COVID-19.